This test is most useful if any of these apply to you.
Urinary FIGlu can rise when a folate-dependent step in protein breakdown is impaired. Folate deficiency is one explanation, but vitamin B12 deficiency, liver disease, and an inherited enzyme deficiency can produce the same finding. A high result alone doesn't identify which explanation applies.
FIGlu has a long history in the investigation of vitamin deficiencies and inherited metabolic disorders. Its use as a spot urine marker for early nutritional screening or preventive health remains exploratory. There are no widely accepted clinical decision thresholds for those purposes, and testing hasn't been shown to improve long-term health outcomes.
Histidine is one of the building blocks of protein. Your liver breaks it down through several steps that produce urocanic acid, then other intermediate compounds, including FIGlu, before reaching glutamate.
Converting FIGlu to glutamate requires an enzyme and a usable form of folate. The enzyme transfers a small carbon-containing group from FIGlu to folate. When that reaction slows, more FIGlu can accumulate and leave your body in urine.
This test measures FIGlu in an unloaded spot urine sample, with the amount expressed relative to urine creatinine. Creatinine is a waste product formed largely in muscle. Adjusting for it reduces the effect of urine dilution, though differences in creatinine production and kidney function still matter.
Much of the older clinical research used a different procedure: a large oral dose of histidine followed by a timed urine collection. Some older assays also measured FIGlu together with urocanic acid. Those studies explain the biology, but their results and diagnostic performance can't be transferred directly to an unloaded spot sample.
Folate deficiency can interfere with the production of new blood cells and eventually cause megaloblastic anemia. Red blood cells are often oversized, and too few reach the circulation. Deficiency can also exist before anemia develops; it hasn't been established that spot urine FIGlu detects it earlier or more reliably than blood testing.
Historical histidine-loading studies found increased FIGlu in some people with folate deficiency, but the test missed others and could be abnormal for unrelated reasons. In one study, FIGlu alone identified 19 of 27 people with excessive combined excretion of FIGlu and urocanic acid. That was a comparison with another biochemical measurement, not a validated sensitivity estimate for diagnosing folate deficiency.
Vitamin B12 helps recycle folate into forms that other reactions can use. Without enough B12, folate can accumulate in its methylated form while other usable forms become scarce. This is called the methylfolate trap. It helps explain why FIGlu can rise in B12 deficiency even when folate intake is adequate.
Older studies documented abnormal urinary histidine breakdown products in pernicious anemia and other B12-related disorders. Pernicious anemia develops when autoimmune damage to the stomach impairs B12 absorption. FIGlu cannot reliably distinguish this problem from folate deficiency, and an ordinary spot result hasn't been validated as a stand-alone measure of the folate trap.
Persistently marked FIGlu excretion can occur in glutamate formiminotransferase deficiency. This condition results from disease-causing changes in both copies of the FTCD gene, usually one inherited from each parent. Affected people can have substantial urinary FIGlu despite adequate folate and B12.
Early reports described children with developmental problems and anemia, but many were investigated because they already had symptoms. A later study followed 18 children identified through newborn screening, with follow-up averaging about five years. Three needed individualized education plans for developmental delay; none had profound intellectual disability or profound anemia. Most were asymptomatic.
That small childhood study is reassuring, but it doesn't establish lifetime outcomes. The amount of FIGlu in urine alone doesn't predict how someone with FTCD deficiency will develop or whether treatment is needed. The urine measurement is a changing biochemical result; confirming the inherited cause requires a separate genetic evaluation.
A study of 330 Korean adults measured FIGlu in fasting spot urine, adjusted for creatinine. Higher levels were associated with stiffer arteries, assessed by the speed of a pressure wave traveling between the arm and ankle. The association persisted after adjustment for several cardiovascular risk factors.
A separate analysis of 529 Korean adults found an association between urinary FIGlu and metabolic syndrome. Metabolic syndrome combines abnormalities in waist size, blood pressure, blood fats, and blood sugar. The FIGlu association was no longer independent after accounting for insulin resistance, so it didn't establish a separate metabolic risk signal.
Both studies examined people at one point in time. They didn't establish whether FIGlu predicts future heart attacks or diabetes, whether folate deficiency explained the associations, or whether lowering FIGlu would reduce risk.
Severe malnutrition shows why FIGlu needs context. In one historical study, more than 80% of infants with protein malnutrition excreted excessive histidine breakdown products after a histidine load. These products included both FIGlu and urocanic acid. Some children had impaired breakdown at an earlier step, so FIGlu could remain low despite folate-related abnormalities.
Liver disease can also disturb this pathway. Historical studies found abnormal FIGlu excretion after histidine loading in people with liver disorders, but an isolated spot urine result cannot establish liver disease or its severity.
Small studies and case reports have described increased FIGlu in people already diagnosed with tumors, leukemia, or myeloma. These findings don't establish a role for FIGlu in cancer screening, and they don't make an isolated high result evidence of cancer.
A low result doesn't establish that folate or B12 status is adequate. Less histidine entering the breakdown pathway can reduce FIGlu output. Rare inherited disorders affecting an earlier step, such as histidinemia, can also reduce its production.
Repeated measurements may show whether an unusual result persists, but there is no validated amount of change in spot urine FIGlu that proves improved folate status or better health. A falling value has to be interpreted alongside the cause of the original elevation, symptoms, and established blood markers.
Evidence-backed interventions that affect your Formiminoglutamic Acid (FIGlu) level
Formiminoglutamic Acid (FIGlu) is best interpreted alongside these tests.
Formiminoglutamic Acid (FIGlu) is included in these pre-built panels.
See the chemical trail your metabolism leaves behind, and explore where your energy, gut, and nutrient pathways may be under strain.
A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.
90 biomarkers